Montenegro CINMED Medical Device Register Analysis: 15,179 Records
A data-driven teardown of Montenegro's CINMED Register of Medical Devices: 15,179 records, EU-aligned risk classes, IVD share, product categories, and local-holder concentration.
Montenegro CINMED Medical Device Register Teardown
Montenegro is a small but strategically useful Western Balkan market for medical device manufacturers, and its national register is maintained by the Institute for Medicines and Medical Devices of Montenegro (CINMED) — in Montenegrin, Institut za lijekove i medicinska sredstva Crne Gore. Like Serbia, Montenegro operates an EU-aligned, CE-reliant regime, but it remains outside the EU and EEA and requires a standalone national registration before a device can be placed on the market. That mandatory national step makes the CINMED register the authoritative read on who is actually authorized to sell in Montenegro — and through which local partner.
A teardown of the CINMED Register of Medical Devices (snapshot compiled on June 22, 2026) reveals a market defined by two structural facts: it is sharply IVD-skewed, and its local-representative layer is highly concentrated. The headline picture:
- Total Registered Records: 15,179 medical device records, each with a unique device ID.
- Unique Generic Products: 4,522 unique generic device names — a high generic-to-record ratio that signals the same product types registered repeatedly across brand variants and local holders.
- Marketing Authorisations: 4,291 unique marketing authorisation numbers, showing that most records carry their own authorisation rather than being bundled under a single decision.
- Unique Local Holders: 114 unique local holders of entry in the register (
holder_of_entry_in_register), the entities that mediate market access for manufacturers not established in Montenegro. - Unique Manufacturers: 1,245 unique manufacturers represented in the register.
- EU-Aligned Risk-Class Split: The largest class label is Other IVD (Ostala IVD) at 5,322 records, followed by Class I at 2,601, Class IIa at 1,841, Class IIb at 1,261, and Class III at 1,000. Combined IVD-class records reach 8,101 (53.4%) of the entire register.
- Local-Holder Concentration: The representative layer is tightly concentrated. OSMI RED-D D.O.O. Podgorica leads with 2,053 records (13.5%), followed by URION D.O.O. Podgorica with 2,006 (13.2%), ADOC D.O.O. with 1,465 (9.6%), FARMONT M.P. D.O.O. Danilovgrad with 1,277 (8.4%), and FARMALAB D.O.O. Podgorica with 844 (5.6%). The top five holders together control 7,645 records (50.4%) — more than half the entire register.
- Leading Manufacturers: Roche Diagnostics GmbH dominates with 1,350 records, far ahead of Abbott GmbH (302), Beckman Coulter Inc. (227), and Medtronic Inc. (201).
This teardown sizes the Montenegrin market, maps its EU-aligned risk-class structure, quantifies local-holder and manufacturer concentration, and translates the data into market-entry decisions. For the regional picture, it pairs with our North Macedonia MALMED medical device registry teardown and our companion Serbia ALIMS medical device register analysis.
Methodology note: This analysis is based on a compiled snapshot of the CINMED Register of Medical Devices dated June 22, 2026. Counts are computed directly from that public register extract by MedDeviceGuide. An important data boundary: the public CINMED register exposes the manufacturer name and the local holder of entry in register, but it does not expose a separate manufacturer-country-of-origin field. This teardown therefore reports manufacturer-name and local-holder concentration rather than country-of-origin shares.
Montenegro's Regulatory Framework: CINMED and the Law on Medical Devices
CINMED is Montenegro's national competent authority for medical devices, working alongside the Ministry of Health. Its responsibilities include maintaining the national register of medical devices and manufacturers, authorizing importation, approving clinical investigations, monitoring vigilance, and coordinating with international regulators. The legal basis is the Law on Medical Devices (Official Gazette of Montenegro No. 024/19), supplemented by the Rulebook on recognition of foreign documents and the CE mark and on the registration of medical devices (Official Gazette No. 085/22).
Three features of this framework shape market entry. First, national registration is mandatory and standalone: unlike an EU member state, Montenegro does not accept CE marking or another EU member-state authorization as automatic market access — a CE certificate supports the conformity assessment, but a separate CINMED registration is still required. Second, manufacturers not established in Montenegro must appoint a Montenegro-based authorized representative (the local "holder of entry in register") with a registered seat or residence in the country; this is distinct from the EU Authorized Representative role. Third, the classification system is EU-aligned at four classes — I, IIa, IIb, and III for medical devices, with IVDs following the List A / List B / Self-testing / Other scheme, and CINMED relies on the manufacturer's CE-mark documentation rather than performing an independent technical review of devices that already hold valid CE certificates.
According to the official CINMED instruction for applicants, the documentation set typically includes the application form, the Declaration of Conformity, the relevant EC/CE certificates, ISO 13485 evidence, and a registration decision for the foreign manufacturer in CINMED's Register of Manufacturers. Consultancy sources place the registration timeline at roughly 90 days and the resulting marketing authorization validity at five years, renewable.
What is the volume and EU-aligned risk-class distribution of medical devices in Montenegro's CINMED register?
The CINMED register contains 15,179 medical device records, each with a unique device ID. These map to 4,522 unique generic names and are supported by 4,291 unique marketing authorisation numbers — meaning the register is structured as close to one authorisation per product record, with relatively little bundling. The same generic device type appears, on average, a little over three times across different brand variants and holders, which is lower replication than larger Balkan markets and reflects Montenegro's smaller commercial footprint.
Risk-Class Breakdown
The class field carries EU-aligned labels:
| Risk Class (CINMED label) | Records | Share of Register |
|---|---|---|
| Other IVD (Ostala IVD) | 5,322 | 35.1% |
| Class I | 2,601 | 17.1% |
| Class IIa | 1,841 | 12.1% |
| Class IIb | 1,261 | 8.3% |
| Class III | 1,000 | 6.6% |
| IVD List C (C) | 928 | 6.1% |
| IVD List A (A) | 897 | 5.9% |
| IVD List B (B) | 666 | 4.4% |
| Class Is | 276 | 1.8% |
| IVD List D (D) | 169 | 1.1% |
| IVD Lista B | 77 | 0.5% |
| IVD Lista A | 42 | 0.3% |
The defining feature is how IVD-heavy Montenegro is. Combining every IVD-class label (Other IVD, List A, List B, List C, List D, Lista A, Lista B) yields 8,101 records, or 53.4% of the entire register — a higher IVD share than the larger Serbian or North Macedonian markets. More than half of all registered records in Montenegro are in-vitro diagnostics. On the non-IVD side, Class I (2,601) is the largest non-IVD class and Class III reaches 1,000 records (6.6%) — a meaningfully higher Class III share than Serbia's 5.1%, suggesting a comparatively deeper implant and high-risk-device footprint relative to the register's size.
Which product categories dominate the Montenegrin medical device register?
The category breakdown corroborates the IVD skew and adds therapeutic texture. In Vitro Diagnostics is by far the largest product category:
| Product Category | Records |
|---|---|
| In Vitro Diagnostic devices | 8,108 |
| Single-use (disposable) devices | 2,272 |
| Reusable devices | 484 |
| Dental devices | 447 |
| Hospital / apparatus equipment | 404 |
| Non-active implantable devices | 393 |
| Ophthalmic and optical devices | 605 |
| Medical equipment, accessories, software, consumables | 546 |
| Electro-mechanical devices | 265 |
| Devices for persons with disabilities | 251 |
IVD at 8,108 records is more than three times the next-largest category (single-use devices at 2,272). This concentration explains why the leading manufacturers are overwhelmingly diagnostics companies (Roche, Abbott, Beckman Coulter, Siemens) and why the leading local holders are frequently diagnostics-oriented distributors. Reusable devices (484), hospital apparatus (404), and non-active implants (393) form a much smaller capital-equipment and implant tail — useful context for manufacturers in those segments, who face a comparatively less crowded field than IVD entrants.
Who are the leading local holders of entry in Montenegro, and how concentrated are they?
Because a foreign manufacturer must appoint a Montenegro-based holder of entry in the register, the holder_of_entry_in_register field is the decisive commercial gatekeeper. The concentration here is the single most important finding in the Montenegrin register:
| Local Holder of Entry | Records | Share |
|---|---|---|
| OSMI RED-D D.O.O., Podgorica | 2,053 | 13.5% |
| URION D.O.O., Podgorica | 2,006 | 13.2% |
| ADOC D.O.O., Belgrade (Podgorica representative office) | 1,465 | 9.6% |
| FARMONT M.P. D.O.O., Danilovgrad | 1,277 | 8.4% |
| FARMALAB D.O.O., Podgorica | 844 | 5.6% |
| MEDICAL SOLUTIONS D.O.O. | 528 | 3.5% |
| YUNYCOM D.O.O. (Belgrade – Herceg Novi) | 494 | 3.3% |
| MEDICA D.O.O., Podgorica | 460 | 3.0% |
The top five holders together control 7,645 records, or 50.4% of the entire register. By any standard this is highly concentrated — and it is the opposite of the fragmented representative landscapes seen in some larger markets. Two of the top five (OSMI RED-D at 13.5% and URION at 13.2%) are neck-and-neck at the top, each controlling roughly one in eight registered records; together with ADOC, FARMONT, and FARMALAB, five firms mediate the majority of market access.
This has direct strategic consequences. First, partner selection is high-stakes and constrained: because a handful of firms already hold half the register, a manufacturer's choice of local representative materially determines competitive positioning, and the most-established holders may have category or brand conflicts with existing principals. Second, several top holders (ADOC, YUNYCOM) are explicitly linked to Belgrade-based parent companies with Podgorica representative offices, reflecting the integrated Serbia–Montenegro distribution corridor — a manufacturer that registers in both markets can sometimes leverage the same regional partner. Third, the concentration creates a renewal and vigilance bottleneck: with so many records concentrated in a few holders, the operational reliability of those holders across the five-year authorization cycle is a genuine commercial risk that manufacturers should diligence before appointing them.
Which foreign manufacturers lead the Montenegrin register?
Ranking the manufacturer field confirms that Montenegro's IVD intensity dictates its manufacturer leaderboard:
| Manufacturer | Records |
|---|---|
| Roche Diagnostics GmbH | 1,350 |
| Abbott GmbH | 302 |
| Beckman Coulter Inc. | 227 |
| Medtronic Inc. | 201 |
| Abbott Ireland Diagnostics Division | 194 |
| Siemens Healthcare Diagnostics, Inc. | 186 |
| Boston Scientific Corporation | 186 |
| Siemens Healthcare Diagnostics Products Limited | 177 |
Roche Diagnostics GmbH is the overwhelming leader with 1,350 records — nearly 9% of the entire register on its own, and more than four times the second-ranked manufacturer. This is a direct consequence of the IVD-heavy category mix: Roche's diagnostics portfolio, registered through its local partners, dominates the largest product category. The next tier — Abbott (302), Beckman Coulter (227), and two Siemens Healthcare entities (186 and 177) — are likewise diagnostics-led. Medtronic (201) and Boston Scientific (186) are the leading non-IVD, implant-and-active-device manufacturers, consistent with the register's meaningful Class III and implant tail. As noted in the methodology, CINMED does not expose a manufacturer-country field, so these shares are reported by manufacturer name rather than by country of origin.
Class III manufacturers: the high-risk competitive set
Within Class III specifically, the competitive set shifts away from diagnostics toward orthopedic and cardiovascular implants. The Class III manufacturer leaders are MEDTRONIC INC. (129 records), Abbott Medical (100), Permedica S.p.a. (57), Boston Scientific Corporation (53), and DePuy Ireland UC (36) — a classic orthopedic-and-cardiovascular implant roster. For an implant manufacturer, this is the relevant benchmarking set, and it is striking that a market of Montenegro's size already carries this depth of high-risk implant brands through its concentrated holder layer.
How valid is the Montenegrin register, and what does the renewal pipeline look like?
Examining the authorisation_expiration_date field shows that Montenegro's register is somewhat less clean than Serbia's, but still predominantly live. Of the records carrying an expiry date, 2,721 (17.9%) had expired as of June 22, 2026, while 11,233 (74.0%) remained valid (the remainder carry no expiry date). So roughly three-quarters of the register is active, and the headline 15,179-record count is a reasonable — if slightly generous — read of the authorized market.
The renewal pipeline is concentrated in a three-year horizon:
| Expiry Year | Records |
|---|---|
| 2027 | 3,078 |
| 2029 | 2,497 |
| 2026 | 1,996 |
| 2028 | 1,891 |
| 2031 | 1,268 |
Roughly 1,996 records expire in 2026, with the largest wave due in 2027 (3,078). Because CINMED marketing authorizations are valid for five years and renewable, and because the top five holders control half the register, this renewal wave will pass disproportionately through a handful of local holders — concentrating renewal-execution risk in exactly the firms that already dominate market access.
Issuance growth: a market that has been expanding
The marketing_authorisation_date field shows steady recent issuance: 3,067 authorisations in 2025, 2,510 in 2024, 2,483 in 2026 (year-to-date as of the snapshot), 1,756 in 2022, and 1,102 in 2021, against older cohorts of ~600–1,000 per year. Issuance has roughly tripled from the mid-2010s baseline, indicating that Montenegro is an actively growing rather than stagnant device market — relevant context for manufacturers weighing whether the effort of a standalone national filing is justified by trajectory.
How concentrated is the local-holder layer, really?
The 50.4% top-five share already signals tight concentration, but the full curve is even more extreme than that headline suggests. Across all 114 holders of entry:
- Just 2 holders cover 25% of the entire register.
- 5 holders cover 50%.
- 15 holders cover 75%.
- Only 6 holders hold 500 or more records each, while 76 holders hold fewer than 50 records each.
This is an exceptionally top-heavy structure: half of all registered medical devices in Montenegro are mediated by only five firms, and a single representative's renewal failure or portfolio decision can move a material slice of the market. It also means the "long tail" of 114 holders is largely illusory at scale — the dozens of small holders collectively control very little. For a manufacturer, the realistic representative shortlist is roughly six firms (those with 500+ records), not 114, which sharply narrows the diligence burden but also limits genuinely independent options.
Strategic Implications for Market Entry
The data supports four concrete decisions for manufacturers evaluating Montenegro:
- Expect a concentrated, IVD-dominated market. With 53.4% of records in IVD classes and Roche alone holding nearly 9% of the register, IVD entrants should assume a crowded, diagnostics-distributor-led competitive field. Implant and capital-equipment entrants face a smaller but less contested field.
- Treat representative selection as the binding decision. The top five holders control 50.4% of the register, so the choice of local partner materially shapes competitive position. Diligence category conflicts, renewal reliability, and vigilance capability — not just registration count — before appointing a holder.
- Exploit the Serbia–Montenegro corridor where possible. Several top Montenegrin holders are linked to Belgrade-based parents. Manufacturers registering across both Western Balkan markets should evaluate whether a single regional partner can cover both, reducing administrative overhead.
- Budget for the standalone national step. CE marking supports but does not replace CINMED registration, the foreign-manufacturer Register-of-Manufacturers step, Montenegrin-language labeling, and the roughly 90-day timeline and five-year renewal cycle. Build these into the regional filing sequence rather than treating Montenegro as a CE-mark automatic.
How does Montenegro compare to its Western Balkan neighbors?
Montenegro's CINMED register is the smallest of the three EU-aligned Western Balkan markets analyzed here, at 15,179 records — roughly one-quarter the size of Serbia's ALIMS register (57,153) and about three times the size of North Macedonia's MALMED register (5,223). But Montenegro stands out on two structural dimensions that matter more than raw size for partner strategy.
First, Montenegro is by far the most concentrated of the three: the top five local holders control 50.4% of its register, compared with about 16.8% in Serbia and roughly 30% in North Macedonia. Half of all registered devices in Montenegro route through just five firms, and only two holders (OSMI RED-D and URION) account for a quarter of the entire register on their own. A manufacturer entering Montenegro is effectively choosing among a handful of credible partners, not a broad market. Second, Montenegro is the most IVD-intensive of the three: combined IVD classes are 53.4% of its register, versus 39.3% in Serbia, and Roche alone holds nearly 9% of all records. The three markets also differ in data transparency — Serbia's register exposes a manufacturer-country field, whereas Montenegro's exposes manufacturer name and local holder but not country of origin.
The practical upshot is that Montenegro rewards a focused, partner-led entry: the standalone national filing effort is real, but the small number of decisive holders means a manufacturer can diligence the entire relevant partner set quickly, and the high IVD share means IVD entrants should expect a Roche-anchored, diagnostics-distributor-led competitive field while implant makers face a comparatively open Class III segment.
Frequently Asked Questions
Which regulator maintains the Register of Medical Devices in Montenegro?
The Institute for Medicines and Medical Devices of Montenegro (CINMED) maintains the national Register of Medical Devices and the Register of Manufacturers, working alongside the Ministry of Health, under the Law on Medical Devices (Official Gazette No. 024/19).
Does a CE mark allow immediate market access in Montenegro?
No. Montenegro is outside the EU and EEA. A CE certificate and EU Notified Body documentation support CINMED's conformity assessment, but a standalone national registration — and, for manufacturers not established in Montenegro, a Montenegro-based authorized representative (holder of entry in register) — is required before market access.
How concentrated is the local authorized-representative market for medical devices in Montenegro?
Highly concentrated. The top five local holders of entry in the register together control 7,645 records, or 50.4% of the entire 15,179-record register. OSMI RED-D D.O.O. Podgorica leads individually with 2,053 records (13.5%).
How IVD-heavy is the Montenegrin medical device register?
Combined IVD-class records total 8,101, or 53.4% of all 15,179 records — the majority of the register. In Vitro Diagnostics is also the largest product category at 8,108 records.
How long is a CINMED medical device registration valid?
According to consultancy sources, the resulting marketing authorization is valid for five years and is renewable; the registration timeline is roughly 90 days. Verify current timelines and fees directly with CINMED.
Is the CINMED register mostly active records?
Predominantly, but not as cleanly as some peers. As of June 22, 2026, about 74% of dated records remained valid and roughly 18% had expired, with the largest renewal wave due in 2027. The register has also been growing, with annual issuance roughly tripling from the mid-2010s baseline to over 3,000 authorisations in 2025.
Why does Roche dominate the Montenegrin register so heavily?
Because the register is majority-IVD (53.4% of records), and Roche's diagnostics portfolio — registered through its local holders — sits squarely in the largest product category. Roche holds nearly 9% of all records on its own, more than four times the next-largest manufacturer.
Conclusion
Montenegro's CINMED register reveals a small but sharply characterized market: 15,179 records that are majority-IVD (53.4%) and mediated by a tightly concentrated layer of local holders where the top five firms control just over half the register. For foreign manufacturers, the binding decision is partner selection in a concentrated field — and for IVD entrants specifically, the market is Roche-anchored and distributor-led, while implant and active-device makers face a smaller, less crowded opportunity. Pairing Montenegro with Serbia in a single Western Balkan registration sequence, and diligenceing holder reliability across the five-year cycle, are the two highest-leverage moves the data supports.
This article is educational and is not legal, regulatory, or commercial advice for any specific product or company. Registration requirements and fees change; verify current requirements directly with CINMED before acting.
Sources
- CINMED — Register of Medical Devices (official): Institute for Medicines and Medical Devices of Montenegro,
cinmed.me/en/medical-devices/register-of-medical-devices. - CINMED — Registration (Medical Devices) (official):
cinmed.me/en/medical-devices/registration. - CINMED — Instruction for applicants for registration of medical devices (official PDF):
cinmed.me, referencing the Law on Medical Devices (Official Gazette of Montenegro No. 024/19) and the Rulebook on recognition of foreign documents and the CE mark (Official Gazette No. 085/22). - Montenegro Law on Medical Devices: Overview (consultancy): Regdesk,
regdesk.co. - Montenegro Medical Device Registration (consultancy): OMC Medical,
omcmedical.com(timeline and validity references). - Register data (dataset): MedDeviceGuide analysis of the CINMED Register of Medical Devices public extract, snapshot dated June 22, 2026.